Fig. 4: CD133 is targeted by the Combi and SARB hybrid treatments. | Cell Death & Disease

Fig. 4: CD133 is targeted by the Combi and SARB hybrid treatments.

From: Combination of 5-fluorouracil and thymoquinone targets stem cell gene signature in colorectal cancer cells

Fig. 4

(A) Western Blot analysis of CD133 marker in HCT116 and (B) in HT29 cells after 48 h of treatment with TQ 40, 5-FU 15, Combi, and SARB 35 µM. (C) FACS analysis of CD133 population after treatment of HCT116 cells and (D) HT29 cells with Combi and SARB for 48 h. Error bars indicate SEM calculated from three and two independent experiments for HCT116 and HT29, respectively. (E) Protein–protein interaction of the genes which were downregulated under SARB and which belong to PI3K/AKT and WNT signaling pathways generated via STRING. (F) Venn diagram of GEO dataset overlapping with the NanoString PanCancer Pathway Panel dataset. All 770 genes were used from NanoString. (G) Venn diagram of the 77 overlapping genes from (f) with the downregulated genes (green line) and upregulated genes (red line) in CD133− population deriving from the GEO dataset. (J) Table with the four downregulated overlapping genes and five upregulated overlapping genes in Combi and SARB treatment.(H) Western Blot analysis of CD133 in HCT116 parental cells and the seven HCT116 CSC enriched-sub-clones. (I) Western Blot analysis of CD133 expression in ST3 clone after 48 h of treatment with Combi and SARB at different drug concentrations. GAPDH immunoblots served as a loading control. All Western Blot images are representative for at least two independent experiments

Back to article page